MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

Recruiting

Magnetic Resonance Imaging (MRI) Derived Quantitative Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

Who can join

Ages 18 and older · Men

Full eligibility criteria

Inclusion Criteria:

* Patients with known or suspected prostate cancer who have been referred for a diagnostic magnetic resonance imaging (MRI) exam of the prostate, to be followed by an MRI-guided fusion biopsy of the prostate.
* Voluntary written informed consent before the MRI examination.

Exclusion Criteria:

* Subjects incapable of giving informed written consent.
* Subjects who cannot adhere to the experimental protocols for any reason, or have an inability to communicate with the researcher;
* Subjects with psychiatric disorders that affect their ability to consent for themselves will be excluded and not the entire population of patients with psychiatric disorders.
* Prisoners.
* Minor children (under the age of 18 years old).
* Patients with previous treatments (surgery, radiation, focal ablation, hormone or other chemotherapy) for prostate cancer.

About the study

Doctors leading this study hope to learn about a software that researchers at the University of Chicago have developed to help analyze radiographic images (different techniques for taking images that allow doctors to visualize the body's internal structures) of the prostate. Participation in this research will last about 12 months. There is a one-time MRI and 1-2 biopsies and then the investigator would like to follow the participant's progress.

What is being tested

Risk Map Decision Support System (DSS). (other)
Magnetic Resonance Imaging (MRI) (radiation)
Magnetic Resonance Imaging (MRI) Guided Biopsy (procedure)

Sponsor: University of Chicago · Participants: 180 · Started: Apr 26, 2023

Contact the study team

Aytekin Oto, MD · Phone: 773-702-8553

Official record on ClinicalTrials.gov — NCT05710380

Locations in the U.S.

Illinois	University of Chicago Medicine Comprehensive Cancer Center, Chicago
Oregon	Oregon Health & Science University, Portland

Conditions

Prostate Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.